Last updated: 2026-09-08 09:46:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
AYTU BioPharma, Inc. (AYTU) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.18, with a market capitalization of $23.72M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.65 to $3.07. This page covers its latest market performance, valuation, price trends and company information.
$23.72M | |
$2.24 | |
$27,280.00 | |
$0.95 | |
$2.29 | |
15.76K | |
25.96K | |
-- | |
$3.07 | |
$1.65 | |
-- | |
-- |
AYTU BioPharma, Inc. (AYTU) is trading at $2.28 in pre-market trading as of 2026-09-04 20:11:00, down 0.35% ($0.01) from the previous close of $2.29
Pre-market trading shows how investors are pricing AYTU before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, AYTU BioPharma, Inc. (AYTU) moved from $2.24 to $2.18, representing a decline of 2.72% ($0.06).
The stock traded between $2.16 and $2.39 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 16.36 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 37.4%
AYTU is currently trading at $2.18, placing it 37.4% of the way from its 52-week low of $1.65 to its 52-week high of $3.07. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 83 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of AYTU BioPharma, Inc. (AYTU) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.